Annual report
8129.TEDINET S100YHSN
Period2025-04-01 → 2026-03-31
Filed2026-06-24
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 158
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.55T | 2025-04-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥1.52T | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥1.48T | 2023-04-01 → 2024-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.39T | 2022-04-01 → 2023-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.27T | 2021-04-01 → 2022-03-31v | Cons. | Net sales (5-year summary) |
| Operating income | ¥16.6bn | 2025-04-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | ¥18.9bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | ¥16.6bn | 2025-04-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥20.7bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥21.8bn | 2023-04-01 → 2024-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥19.2bn | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥18.2bn | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥26.1bn | 2025-04-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥28.1bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥17.3bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥19.8bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥20.7bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥13.6bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥13.4bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥17.3bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | ¥19.9bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥740.8bn | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥722.8bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥773.4bn | at 2024-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥715.3bn | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥702.4bn | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥469.2bn | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥465.9bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥271.6bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥256.9bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥249.4bn | at 2024-03-31v | Cons. | Net assets |
| Net assets / equity | ¥242.9bn | at 2023-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥241.3bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥87.4bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥86.5bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥83.3bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥78.2bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥128.7bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥81.8bn | at 2023-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥90.0bn | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥19.2bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥26.7bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥59.9bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥9m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥16.3bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥822m | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥4.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥9.1bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥4.3bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥11.0bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥16.3bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥20.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥22.2bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥13.1bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥4.5bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥271.18 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥313.2 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥320.14 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥196.7 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥189.7 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥260.98 | 2025-04-01 → 2026-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥284.22 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥286.79 | 2023-04-01 → 2024-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥180.67 | 2022-04-01 → 2023-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥174.48 | 2021-04-01 → 2022-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥4,193.25 | at 2026-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,099.71 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,969.2 | at 2024-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,623.81 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,415.5 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 36.6% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.5% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.2% | at 2024-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.9% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.3% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 6.6% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.8% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.4% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.6% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.6% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 7,675 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 7,609 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 7,572 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 7,699 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 7,785 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥16.0bn | 2025-04-01 → 2026-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥15.6bn | 2024-04-01 → 2025-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥12.5bn | 2023-04-01 → 2024-03-31v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥13.0bn | 2022-04-01 → 2023-03-31v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥7.3bn | 2021-04-01 → 2022-03-31v | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥6.9bn | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥7.0bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥7.3bn | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥7.6bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥4.9bn | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7.3bn | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.1bn | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥17.2bn | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥16.2bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥14.5bn | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥13.9bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥13.1bn | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥9.7bn | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥4.0bn | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥245.9bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥242.6bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥267.4bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥253.5bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥254.8bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥84.5bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥92.1bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥161.5bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥150.4bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥150.1bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥152.3bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥154.8bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥74.7bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥74.9bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥226.93 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥218.73 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥203.27 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥139.32 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥56.91 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥218.33 | 2025-04-01 → 2026-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥198.34 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥182.03 | 2023-04-01 → 2024-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥127.91 | 2022-04-01 → 2023-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥52.22 | 2021-04-01 → 2022-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥165 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥65 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥32 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,493.03 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,400.68 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,387.4 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,271.65 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,191.82 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 65.6% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.0% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.1% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.0% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.7% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 9.3% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.2% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.7% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.3% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.5% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 73,025,942 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 73,025,942 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 76,431,342 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 78,270,142 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 78,270,142 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 199 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 193 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 192 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 192 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 224 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 71
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2025-04-01 → 2026-03-31 | −¥16m |
| Reconciling Itemsreconciling | depreciation | 2025-04-01 → 2026-03-31 | ¥1.9bn |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2026-03-31 | −¥60.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2026-03-31 | −¥60.7bn |
| Reconciling Itemsreconciling | segment assets | at 2026-03-31 | ¥58.1bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2026-03-31 | −¥2.7bn |
| Dispensing Pharmacyreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥815m |
| Dispensing Pharmacyreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥938m |
| Dispensing Pharmacyreportable segment | employees | at 2026-03-31 | 2811 pure |
| Dispensing Pharmacyreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥100.5bn |
| Dispensing Pharmacyreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥100.5bn |
| Dispensing Pharmacyreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥2m |
| Dispensing Pharmacyreportable segment | segment assets | at 2026-03-31 | ¥61.1bn |
| Dispensing Pharmacyreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥1.4bn |
| Medical Products Manufacturing And Salesreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥958m |
| Medical Products Manufacturing And Salesreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥323m |
| Medical Products Manufacturing And Salesreportable segment | employees | at 2026-03-31 | 111 pure |
| Medical Products Manufacturing And Salesreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥11.6bn |
| Medical Products Manufacturing And Salesreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥2.7bn |
| Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥8.9bn |
| Medical Products Manufacturing And Salesreportable segment | segment assets | at 2026-03-31 | ¥17.5bn |
| Medical Products Manufacturing And Salesreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥282m |
| Medical Products Retailreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥9.4bn |
| Medical Products Retailreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥2.7bn |
| Medical Products Retailreportable segment | employees | at 2026-03-31 | 4329 pure |
| Medical Products Retailreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥1.49T |
| Medical Products Retailreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥1.44T |
| Medical Products Retailreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥50.2bn |
| Medical Products Retailreportable segment | segment assets | at 2026-03-31 | ¥598.0bn |
| Medical Products Retailreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥16.8bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2025-04-01 → 2026-03-31 | ¥11.2bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2025-04-01 → 2026-03-31 | ¥4.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2026-03-31 | ¥1.61T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2026-03-31 | ¥1.55T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥60.7bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2026-03-31 | ¥682.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2026-03-31 | ¥19.3bn |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥8m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥1.8bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥58.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥58.9bn |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥53.5bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥2.3bn |
| Dispensing Pharmacyreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥855m |
| Dispensing Pharmacyreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥891m |
| Dispensing Pharmacyreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥95.6bn |
| Dispensing Pharmacyreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥95.5bn |
| Dispensing Pharmacyreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥22m |
| Dispensing Pharmacyreportable segment | segment assets | at 2025-03-31 | ¥58.7bn |
| Dispensing Pharmacyreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥852m |
| Medical Products Manufacturing And Salesreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥1.8bn |
| Medical Products Manufacturing And Salesreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥166m |
| Medical Products Manufacturing And Salesreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥11.5bn |
| Medical Products Manufacturing And Salesreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥2.6bn |
| Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥8.8bn |
| Medical Products Manufacturing And Salesreportable segment | segment assets | at 2025-03-31 | ¥19.4bn |
| Medical Products Manufacturing And Salesreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥729m |
| Medical Products Retailreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥3.6bn |
| Medical Products Retailreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥2.7bn |
| Medical Products Retailreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.46T |
| Medical Products Retailreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥1.42T |
| Medical Products Retailreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥48.2bn |
| Medical Products Retailreportable segment | segment assets | at 2025-03-31 | ¥585.3bn |
| Medical Products Retailreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥19.0bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥6.4bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥4.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥1.58T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥1.52T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥58.9bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥669.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥21.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,098
| Item | Context | Value | Unit |
|---|---|---|---|
| Payout ratio (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 0.7271 | |
| Number of employees | Prior4YearInstant_NonConsolidatedMember | 224 | |
| Number of employees | Prior3YearInstant_NonConsolidatedMember | 192 | |
| Number of employees | Prior2YearInstant_NonConsolidatedMember | 192 | |
| Number of employees | Prior1YearInstant_NonConsolidatedMember | 193 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 199 | |
| Average number of temporary workers | Prior4YearInstant_NonConsolidatedMember | 26 | |
| Average number of temporary workers | Prior3YearInstant_NonConsolidatedMember | 22 | |
| Average number of temporary workers | Prior2YearInstant_NonConsolidatedMember | 21 | |
| Average number of temporary workers | Prior1YearInstant_NonConsolidatedMember | 22 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 21 | |
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | 0.926 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 1.188 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 1.849 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 2.279 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 2.509 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 1.020 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 1.079 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 1.525 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.502 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 2.022 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | 100 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | 100 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | 53.4 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | 60 | |
| Gross scope1 and2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior6YearDuration_ConsolidatedAccountingGroupMember | 40886 | |
| Gross scope1 and2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | CurrentYearDuration_ConsolidatedAccountingGroupMember | 19886 | |
| Research and development expenses research and development activities | CurrentYearDuration | 173000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 11215000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 73025942 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 73025942 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 73025942 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 73025942 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 12 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 17 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 77 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 180 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 6 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 3373 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 3665 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 109897 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 12606 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 99852 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 280098 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 16 | |
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 227256 | |
| Number of shares held number of units total | CurrentYearInstant_OrdinaryShareMember | 729725 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |